Amgen Said to Boost Bid for Onyx to $130 a Share

Aug. 6 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Olivia Sterns reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)
Blippar: Harnessing the Power of Augmented Reality
30:21 - "Bloomberg West" takes us inside Blippar, a unicorn that's harnessed the power of augmented reality as a tool for mobile advertising and visual search. (Source: Bloomberg)
  • Why Did YouTube Enter the Video Game Streaming Business?
  • Apple's Plans to Compete With Netflix
  • What the Stock Selloff Means for Tech Startups